Cryoport (CYRX, Buy, $66.00) and bluebird bio: Investment Significance of bluebird’s Decision to Temporarily Suspend Sickle Cell Disease Trials of LentiGlobin and Marketing of Zynteglo in Europe
Cryoport (CYRX, Buy, $72.30) Kymriah Sales are Strong and Equity Offering Was Well Received
Cryoport: Comments on Just Completed Equity Offering and Surprising 15% Surge in Stock Price (CYRX, Buy, $73.75)
Cytokinetics: Approval of Merck’s Heart Failure Drug Vericiguat Increases My Confidence for Approval of Omecamtiv
Cytokinetics: A Deep Dive into the Potential for Omecamtiv (CYTK, Buy, $19.86)
Antares: Encouraging Revenue Guidance (ATRS, Buy, $4.00)
Cryoport; How Airlines Might Need Cryoport Dewars for Shipping of COVID-19 Vaccines (CYRX, Buy, $46.43)
Cryoport: Potential Commercial Benefits from COVID-19 Vaccines (CYRX, Buy, $46.43)
What Will Happen to SmithOnStocks
Closing Subscriptions to SmithOnStocks and Issuing Refunds
Are There Implications from the Frenzy over GameStop for Adam Feuerstein
Wall Street is Poised for Disruption, Part 2, February 1, 2021
Wall Street is Poised for Disruption, Part One January 30, 2021
Northwest Biotherapeutics and the Robinhood Trading Phenomenon (NWBO), Buy, $1.59)